Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Promotional Enforcement Still Playing It Safe

Executive Summary

Even with letter citing Spanish video for Oxtellar seizure, US regulatory agency likely to issue record low number of letters this year.

Advertisement

Related Content

Opioid Warning Letter To Cipher Likely Easy Call For US FDA
FDA’s Rx Promo Citations Rise Slightly In 2016; Investigational Drug Promos Scrutinized
DTC Trouble: ‘Attention-Grabbing Visuals’ Undermine Risk Info, FDA Tells Celgene, Sanofi
Remoxy's Woes Stoke Criticism Of FDA's Review Of Abuse-Deterrent Opioids
FDA's Rx Promotion Citation Drought Continued In 2015

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS119464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel